Arpida files iclaprim in Canada
This article was originally published in Scrip
Executive Summary
Arpidahas filed its lead product, the intravenous antibiotic iclaprim, for approval in Canada. The filing is for the treatment of complicated skin and skin structure infection (cSSSI) and includes data from the ASSIST-1 and ASSIST-2 Phase III trials, which showed iclaprim was non-inferior to Pfizer's Zyvox (linezolid) for cSSSI in a group of patients with a high incidence of meticillin-resistant Staphylococcus aureus (MRSA). Iclaprim is a synthetic diaminopyrimidine and Arpida has said it believes the compound may have benefits over Zyvox, an oxazolidinone antibiotic which can cause myelosuppression. The company filed for approval of iclaprim in the US in March and in the EU in July (Scrip Online, March 20th, 2008 and Scrip Online, July 29th, 2008, respectively).
You may also be interested in...
Amgen reveals more details of denosumab's fracture benefit
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Gilead must conduct another study of cystic fibrosis drug, FDA says
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.